CytomX Therapeutics, Inc. (CTMX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference

- Expanded collaboration builds upon research momentum in developing next-generation bispecific immu

- Expanded collaboration builds upon research momentum in developing next-generation bispecific immu

In March, CTMX showcased Varseta-M's potential in late-line metastatic colorectal cancer, although t

SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTM

SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTM

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains CytomX Therapeutics (NASDAQ:CTMX) wi

CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript

CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.1 per share versus the Zacks Consens

CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.10) per share which beat the anal

- Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) Ep

SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: C

Healthcare companies with different market caps offer different rewards and challenges.

CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) was the target of some unusual options tr

Adagene (NASDAQ: ADAG - Get Free Report) and CytomX Therapeutics (NASDAQ: CTMX - Get Free Report) ar

Assenagon Asset Management S.A. decreased its holdings in shares of CytomX Therapeutics, Inc. (NASDA

Piper Sandler analyst Joseph Catanzaro maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overwei

CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) gapped up prior to trading on Thursday af

Barclays analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and r

Jefferies analyst Roger Song maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and raises th

On Tuesday, CytomX Therapeutics announced a public offering of 45.9 million shares at $5.30 per shar

CytomX stock falls after $250 million share sale, even as new colorectal cancer data shows strong re

CytomX Therapeutics (CTMX) has generated significant excitement with strong early data for varsetatu

Guggenheim analyst Michael Schmidt maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and rai

SOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CT

CytomX Therapeutics stock surges 44% after phase I data for Varseta-M in heavily pretreated metastat

Wedbush analyst Robert Driscoll maintains CytomX Therapeutics (NASDAQ:CTMX) with a Outperform and

Boothbay Fund Management LLC purchased a new position in CytomX Therapeutics, Inc. (NASDAQ: CTMX) du

CytomX Therapeutics (CTMX +44.44%), a biotech company that develops conditionally activated biologic

Common StockPreferred StockDebt SecuritiesWarrantsUnitsWe may offer and sell the securities identifi

In addition, CytomX expects to grant the underwriters a 30-day option to purchase up to an additiona

CytomX Therapeutics stock jumps in premarket trading after Phase 1 data for Varseta-M showed tumor r

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains CytomX Therapeutics (NASDAQ:CTMX) wi

JP Morgan analyst Anupam Rama upgrades CytomX Therapeutics (NASDAQ:CTMX) from Neutral to Overweig

Dow Jones index up 500 points; Nebius Group NV shares rise 12.7% on AI agreement with Meta Platforms

NBIS: 17% | Nebius Announced 5-Year $12B AI Infrastructure Agreement With Meta To Provide Dedicated

- Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W

CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.22) per share which missed the an

CytomX Therapeutics (CTMX) will release its Q4 earnings on March 16, with analysts expecting a loss

Guggenheim analyst Michael Schmidt reiterates CytomX Therapeutics (NASDAQ:CTMX) with a Buy and ma

Cantor Fitzgerald analyst Olivia Brayer maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overwe

Barclays analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and r

Barclays analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and r

Guggenheim analyst Michael Schmidt initiates coverage on CytomX Therapeutics (NASDAQ:CTMX) with a